Tremfya Market Set to Reach USD 6.71 Billion by 2032 Driven by Rising Autoimmune Disease Burden and Targeted Biologics Adoption

Tremfya Market Overview and Growth Dynamics

The Tremfya market was valued at USD 3.73 billion in 2024 and is anticipated to grow to USD 6.71 billion by 2032, representing a robust CAGR of 7.63% during 2025-2032. Tremfya (guselkumab), a biologic targeting IL-23, has emerged as a preferred treatment for autoimmune conditions such as moderate-to-severe plaque psoriasis and psoriatic arthritis. Its specificity, favorable safety profile, and long-term efficacy retention make it a compelling choice among healthcare providers and patients seeking long-term disease control.

The global growth of the Tremfya market is underpinned by rising autoimmune disease prevalence, improved diagnosis rates, and preference for targeted immunotherapies. Regulatory approvals, label expansions, and ongoing clinical trials continue to expand Tremfya’s potential use. In June 2024, Janssen Pharmaceuticals launched a Phase III trial evaluating Tremfya in axial spondyloarthritis, signaling potential future indications beyond skin and joint conditions.

Track the Latest Market Developments: Request a Sample Report: https://www.snsinsider.com/sample-request/7785

Market Drivers Supporting Tremfya Adoption and Expansion

The Tremfya market is primarily propelled by the growing burden of autoimmune diseases, especially psoriasis and psoriatic arthritis. Estimates from the National Psoriasis Foundation suggest that over 8 million Americans are affected by psoriasis, emphasizing the demand for effective, long-term biologic therapies. As an IL-23 inhibitor, Tremfya offers sustained remission with fewer side effects compared to older biologics, positioning it as a cornerstone therapy in modern treatment protocols.

Rapid clinical adoption of targeted biologics over TNF-alpha and IL-17 inhibitors is another growth driver. Janssen and other key companies continue to invest heavily in immunology R&D, with Johnson & Johnson alone spending more than USD 15 billion in 2023. More than 100 clinical trials are currently evaluating IL-23 pathways, providing strong momentum for market confidence and future approvals. Favorable reimbursement policies, increasing physician preference, and positive updates in treatment guidelines from AAD and EULAR also contribute to growth, enabling Tremfya to expand its prescription base.

Tremfya Market Challenges and Restraints

Despite strong growth prospects, the Tremfya market faces challenges related to high treatment costs, limited accessibility in low- and middle-income regions, and emerging biosimilar competition. Annual therapy costs can exceed USD 60,000, limiting patient access, particularly in markets with inadequate insurance coverage. Cold chain requirements, manufacturing capacity constraints, and regulatory complexities may also restrict global availability.

The nascent biosimilar pipeline poses a future threat, potentially introducing price pressures by the early 2030s. Additionally, patient compliance challenges, such as needle aversion and the demand for oral alternatives, may hinder adoption in certain segments. Approval delays or recalls could further affect market stability, emphasizing the need for sustained regulatory oversight and quality assurance.

Application-Based Segmentation Analysis

In 2024, the plaque psoriasis segment dominated the Tremfya market with 87.03% revenue share, driven by high patient prevalence and strong clinical outcomes. Increased awareness of biologic therapies, coupled with KOL preference for IL-23 inhibitors for long-term disease control, further supported market uptake.

The psoriatic arthritis (PsA) segment is projected to achieve the strongest growth due to expanding clinical evidence of Tremfya’s efficacy in reducing joint inflammation and stiffness. Rheumatologists are increasingly incorporating Tremfya in treatment protocols, signaling growth opportunities beyond dermatology.

Distribution Channel Insights

Hospital pharmacies led the Tremfya distribution market in 2024, accounting for 51.23% of revenue, due to hospital-based biologic initiation and streamlined institutional ordering. Online pharmacies are expected to grow fastest, fueled by digital health adoption, home delivery convenience, patient confidence in regulated e-pharmacies, and direct-to-consumer models post-pandemic.

Accelerated Market Demand: Find Comprehensive Insights and Trends in Our Full Report: https://www.snsinsider.com/reports/tremfya-market-7785

Regional Insights and Market Trends

North America accounted for 85.48% of global revenue in 2024, driven by high psoriasis prevalence, established biologics uptake, and well-developed healthcare infrastructure. The U.S. market was valued at USD 2.41 billion in 2024 and is forecasted to reach USD 4.14 billion by 2032 at a CAGR of 7.05%. Canada shows gradual growth due to increased specialty drug coverage and dermatologist awareness, while Mexico is growing from public-private investments and urban patient concentration.

Europe demonstrates steady expansion, with Germany leading adoption due to early biologic uptake and favorable reimbursement. The UK’s market growth is propelled by NHS initiatives and physician preference, whereas France, Italy, Poland, and Turkey are emerging due to aging populations, increasing psoriasis diagnosis, and healthcare reforms supporting biologics.

The Asia Pacific region is expected to witness the highest growth, led by Japan’s high-quality healthcare system and extensive biologic coverage. China is emerging as a key growth driver due to increasing psoriasis prevalence, regulatory fast-tracking of biologics, and growing middle-class access. India and South Korea are also contributing to growth via government health schemes and improved access to biologics.

Key Market Participants

((Johnson & Johnson Services, Inc., Janssen Pharmaceuticals, Eli Lilly and Company, AbbVie Inc., Novartis AG, Pfizer Inc., Bristol-Myers Squibb Company))

Recent Developments Driving Tremfya Growth

In June 2024, Johnson & Johnson reported clinical trial results showing Tremfya significantly improved symptoms in patients with active psoriatic arthritis, reinforcing its efficacy in joint and skin management. In March 2025, the FDA approved Tremfya as the first IL-23 inhibitor providing both subcutaneous and intravenous induction for Crohn’s disease, offering enhanced flexibility and patient access. Real-world data from over 20,000 patients reported in March 2024 confirmed sustained disease clearance and long-term remission, strengthening market confidence.

Future Outlook and Market Potential

The Tremfya market is poised for sustained growth through 2032 as new indications, expanded approvals, and increasing global manufacturing capacity improve patient access. Continued R&D, coupled with favorable treatment guidelines and the growing adoption of targeted biologics, is expected to drive market expansion, particularly in emerging regions. While high costs and access limitations pose challenges, Tremfya’s clinical efficacy, safety profile, and long-term benefits will maintain its market leadership.

Conclusion

Rising autoimmune disease prevalence, strong R&D investments, and evolving treatment guidelines are propelling the Tremfya market toward an anticipated USD 6.71 billion by 2032. Tremfya’s effectiveness as an IL-23 inhibitor, coupled with expanding indications and global adoption, positions it as a key biologic in the fight against psoriasis and psoriatic arthritis. The combination of clinical validation, regulatory support, and digital pharmacy growth ensures Tremfya remains a central focus for healthcare providers and patients worldwide.

Other Trending Reports

Eyelid Surgery Market

Hirsutism Market

Pharmacogenomics Technology Market

Legionella Testing Market